14.3 Weight Reduction and Long-term Maintenance Study of WEGOVY Injection in Pediatric Patients Aged 12 Years and Older with Obesity Overview of Clinical Trial in Pediatric Patients WEGOVY injection was evaluated to reduce excess body weight in pediatric patients aged 12 years of age and older with obesity in a 68-week, double-blind, randomized, parallel group, placebo-controlled, multi-center trial in 201 pubertal pediatric patients aged 12 years and older with BMI corresponding to 95th percentile standardized for age and sex (Study 10) (NCT#04102189)
Causes of Aphthous Stomatitis are not Well Understood In most cases the only symptoms are the appearance of the ulcer inside the mouth and the associated pain, but in severe cases this discomfort can interfere with normal eating and can cause unintentional weight loss and scarring
Preserving lean muscle supports metabolic health and long-term results
Efficacy determination was based on the effect of WEGOVY injection on resolution of steatohepatitis without worsening of liver fibrosis and on at least one stage improvement in liver fibrosis without worsening of steatohepatitis, on post-baseline liver biopsies collected at 72 weeks
This suggests that dose selection involves balancing maximum efficacy against tolerability for individual patients
